↓ Skip to main content

The cardiovascular safety of incretin-based therapies: a review of the evidence

Overview of attention for article published in Cardiovascular Diabetology, January 2013
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (73rd percentile)
  • Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

twitter
1 tweeter
patent
1 patent

Citations

dimensions_citation
38 Dimensions

Readers on

mendeley
72 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The cardiovascular safety of incretin-based therapies: a review of the evidence
Published in
Cardiovascular Diabetology, January 2013
DOI 10.1186/1475-2840-12-130
Pubmed ID
Authors

John R Petrie

Abstract

Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in people with diabetes and therefore managing cardiovascular (CV) risk is a critical component of diabetes care. As incretin-based therapies are effective recent additions to the glucose-lowering treatment armamentarium for type 2 diabetes mellitus (T2D), understanding their CV safety profiles is of great importance. Glucagon-like peptide-1 (GLP-1) receptor agonists have been associated with beneficial effects on CV risk factors, including weight, blood pressure and lipid profiles. Encouragingly, mechanistic studies in preclinical models and in patients with acute coronary syndrome suggest a potential cardioprotective effect of native GLP-1 or GLP-1 receptor agonists following ischaemia. Moreover, meta-analyses of phase 3 development programme data indicate no increased risk of major adverse cardiovascular events (MACE) with incretin-based therapies. Large randomized controlled trials designed to evaluate long-term CV outcomes with incretin-based therapies in individuals with T2D are now in progress, with the first two reporting as this article went to press.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 72 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 3%
Unknown 70 97%

Demographic breakdown

Readers by professional status Count As %
Student > Master 13 18%
Researcher 12 17%
Other 10 14%
Student > Postgraduate 10 14%
Student > Ph. D. Student 8 11%
Other 11 15%
Unknown 8 11%
Readers by discipline Count As %
Medicine and Dentistry 47 65%
Pharmacology, Toxicology and Pharmaceutical Science 5 7%
Agricultural and Biological Sciences 4 6%
Nursing and Health Professions 2 3%
Social Sciences 2 3%
Other 2 3%
Unknown 10 14%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 November 2016.
All research outputs
#3,387,527
of 12,483,518 outputs
Outputs from Cardiovascular Diabetology
#163
of 737 outputs
Outputs of similar age
#60,357
of 235,684 outputs
Outputs of similar age from Cardiovascular Diabetology
#10
of 55 outputs
Altmetric has tracked 12,483,518 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 737 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 235,684 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 55 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.